Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

EVOTEC : JUMP-STARTS BIOLOGICS WITH ACQUISITION OF JUST BIOTHERAPEUTICS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2019 | 04:30pm EDT

DGAP-News: Evotec SE / Key word(s): Takeover
EVOTEC JUMP-STARTS BIOLOGICS WITH ACQUISITION OF JUST BIOTHERAPEUTICS

20.05.2019 / 22:25
The issuer is solely responsible for the content of this announcement.


  • EVOTEC'S OFFERING OF INTEGRATED SOLUTIONS EXTENDED TO BIOLOGICS
  • ADDITION OF LONGSTANDING BIOLOGICS EXPERTISE BASED ON KEY TALENTS, INNOVATIVE ML (MACHINE LEARNING) DRIVEN TECHNOLOGIES AND SOPHISTICATED PROCESSES
  • EXPANDING EVOTEC'S US FOOTPRINT IN SEATTLE, A BIOLOGICS HUB
  • ACCRETIVE TO EVOTEC'S REVENUE GROWTH
  • CONSIDERATION OF UP TO $ 90 M (APPROX. EUR 81 M) INCLUDING POTENTIAL EARN-OUTS 2019 - 2022 (E)
  • TRANSACTION PAID IN CASH
  • CONFERENCE CALL SCHEDULED FOR TUESDAY, 21 MAY 2019, AT 01.30 PM (CEST) TO INTRODUCE THE TRANSACTION


Hamburg, Germany, 20 May 2019: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio"), for up to $ 90 m including potential performance-based earn-out components expected within the next three years. Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for design, development, and manufacturing of biologics. Founded only in 2014/15, Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA. The acquisition is expected to close in the second quarter 2019.

Opens new growth opportunites as Evotec diversifies into biologics

The acquisition of Just.Bio will add considerable business opportunities for further acceleration of Evotec's long-term strategy to be the industry partner of choice for external end-to-end innovation. Evotec's drug discovery and development value proposition today is to offer the highest quality integrated services mainly in the field of small molecules. The acquisition grows Evotec's business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Like Evotec in small molecules, Just.Bio is defined by its excellence in science and technology, defined outcomes, smart and highly efficient solutions for developing and manufacturing of biologics at highest standards, thus making an excellent fit.

Just.Bio's capabilities and expertise comprise an in-house, integrated technology platform, J.DESIGN, enabling smart and efficient biologics' drug development from design and lead optimisation to manufacturing:

  • J.MDTM is a technology-based process development tool using Abacus(TM) as machine learning-based computer-aided design tool to predict and select optimial molecules for further development
  • JP3(R) includes lab and computational tools for rapid development of a high-yielding manufacturing process along with a cGMP early clinical manufacturing facility
  • Significant further potential lies in the company's J.POD(R) technology for flexible and modular larger scale manufacturing of clinical and commercial stage biologics

Transaction structure reflects value potential

During recent years, Just.Bio has been able to attract a diversified customer portfolio resulting in strong financial growth. With reported 2018 revenues of approx. EUR 20 m, Just.Bio was able to achieve revenue growth rates that are above the general market growth. Evotec will pay a total consideration of up to $ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential earn outs in the next three years. The initial consideration upon closing is $ 60 m1) (approx. EUR 54 m; EUR/$ fx rate of 1.117). The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash to a syndicate of institutional investors of ARCH Venture Partners, Merck & Co., Lilly Asia Ventures and the Bill & Melinda Gates Foundation. The acquisition will add to Evotec's revenue growth and will strengthen Evotec's overall strategic plan. The potential guidance update will be given latest upon reporting of half-year 2019 figures. Just.Bio will be financially fully consolidated under the Evotec Group.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "We are excited about the acquisition and warmly welcome Just.Bio's expert team as a new part of the Evotec family and also welcome Dr Jim Thomas in his new management role EVP, Global Head, Biotherapeutics, President US Operations. Broadening our platform into biologics has always been key to our strategy. With this acquisition we finally found the perfect match to complement our leadership in small molecules."

Dr James Thomas, Chief Executive Officer of Just.Bio, commented: "Combining Just.Bio with Evotec creates a technological powerhouse that will fuel our long-term mission to make important biologics accessible to patients worldwide. We are thrilled to be part of the Evotec family."

1) Subject to customary adjustments for net debt and net working capital

 

Webcast/Conference Call
Evotec invites you to join a conference call to provide information regarding the acquisition of Just.Bio. The conference will be held in English.

Conference call details

Date: 21 May 2019
Time: 01.30 pm CEST (07.30 am EDT/ 12.30 pm BST)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 0 236 006 663
From the UK: +44 20 3009 2470
From the USA: +1 877 423 0830
Access Code: 75781959#

A simultaneous slide presentation for participants dialling in via phone is available at https://webcasts.eqs.com/evotec20190521/no-audio.

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialling +49 69 20 17 44 222 (Germany) or +44 20 3364 5150 (UK) and in the USA by dialling +1 844 307-9362. The access code is 3155459882#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports.


ABOUT JUST BIOTHERAPEUTICS
Just.Bio is a unique platform company that integrates the design, development and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics, from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus and passion is to create access and value for a global market through scientific and technological innovation. For more information visit
 http://just.bio.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,600 employees provide the highest quality
stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including, Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, VP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com



20.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 813735

 
End of News DGAP News Service

813735  20.05.2019 

fncls.ssp?fn=show_t_gif&application_id=813735&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
06/13EVOTEC : bags US$23.8m to fight tuberculosis
AQ
06/12EVOTEC : bags $23.8m to fight tuberculosis
AQ
06/11EVOTEC : receives $ 23.8 m grant to join the global fight against tuberculosis
AQ
06/10EVOTEC : Receives $ 23.8 m grant to join the global fight against tuberculosis
EQ
06/06EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
06/05EVOTEC : And celgene further expand ipsc collaboration including new cell type
EQ
05/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
05/31EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
05/29EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
05/21EVOTEC : jump-starts biologics with acquisition of Just Biotherapeutics
AQ
More news
Financials (€)
Sales 2019 414 M
EBIT 2019 73,4 M
Net income 2019 53,5 M
Finance 2019 6,17 M
Yield 2019 -
P/E ratio 2019 58,96
P/E ratio 2020 57,65
EV / Sales 2019 7,80x
EV / Sales 2020 6,78x
Capitalization 3 240 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,5 €
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG31.59%3 664
IQVIA HOLDINGS INC21.63%26 223
LONZA GROUP29.21%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION22.20%17 061
EXACT SCIENCES CORPORATION73.98%13 037